Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and the New to Determine What to Do
Seth P. Lerner, MD, discusses the optimal therapy for T1 high-grade (T1HG) bladder cancer and considers the future of treatment.
Read MoreSelect Page
Posted by Seth P. Lerner, MD, FACS | Apr 2023
Seth P. Lerner, MD, discusses the optimal therapy for T1 high-grade (T1HG) bladder cancer and considers the future of treatment.
Read MorePosted by Martin M. Miner, MD | Apr 2023
Martin M. Miner, MD, discusses the role of testosterone therapy in improving men’s health outcomes, including in prostate cancer.
Read MorePosted by Wesley A. Mayer, MD | Apr 2023
Wesley A. Mayer, MD, and Marisa M. Clifton, MD, FACS, FPMRS, debate residency training and ponder whether faculty are too hard or too soft on residents.
Read MorePosted by E. David Crawford, MD | Apr 2023
E. David Crawford, MD, interviews Lon and his partner Kacy about Lon’s 5-year treatment experience with advanced prostate cancer.
Read MorePosted by Preston C. Sprenkle, MD | Apr 2023
Preston C. Sprenkle, MD, discusses the OPTIMUM trial examining micro-ultrasound, MRI fusion, and the combination of these in prostate cancer diagnosis.
Read More